Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis-Reference-Cited by-同舟云学术

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Published:2010-09-16 Issue:12 Volume:363 Page:1117-1127
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Verstovsek Srdan,Kantarjian Hagop,Mesa Ruben A.,Pardanani Animesh D.,Cortes-Franco Jorge,Thomas Deborah A.,Estrov Zeev,Fridman Jordan S.,Bradley Edward C.,Erickson-Viitanen Susan,Vaddi Kris,Levy Richard,Tefferi Ayalew

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1002028

Cited by 1006 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study;Annals of Hematology;2024-09-07

2. Ruxolitinib Plus Basiliximab Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease in Unrelated Cord Blood Transplantation: A Large-Scale Study;Transplantation and Cellular Therapy;2024-09

3. Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms;Arteriosclerosis, Thrombosis, and Vascular Biology;2024-09

4. Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study;Cancer;2024-07-30

5. Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms;Frontiers in Pharmacology;2024-07-22